البلد: كندا
اللغة: الإنجليزية
المصدر: Health Canada
LEVONORGESTREL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL; ETHINYL ESTRADIOL; LEVONORGESTREL
BAYER INC
G03AB03
LEVONORGESTREL AND ESTROGEN
125MCG; 30MCG; 40MCG; 50MCG; 30MCG; 75MCG
TABLET
LEVONORGESTREL 125MCG; ETHINYL ESTRADIOL 30MCG; ETHINYL ESTRADIOL 40MCG; LEVONORGESTREL 50MCG; ETHINYL ESTRADIOL 30MCG; LEVONORGESTREL 75MCG
ORAL
28
Prescription
CONTRACEPTIVES
Active ingredient group (AIG) number: 0618648001; AHFS:
APPROVED
2007-03-08
_TRIQUILAR Product Monograph _ _Page 1 of 54_ PRODUCT MONOGRAPH PR TRIQUILAR ® 21 PR TRIQUILAR ® 28 0.05 mg levonorgestrel and 0.03 mg ethinyl estradiol tablets 0.075 mg levonorgestrel and 0.04 mg ethinyl estradiol tablets 0.125 mg levonorgestrel and 0.03 mg ethinyl estradiol tablets USP Oral Contraceptive Bayer Inc. 2920 Matheson Boulevard East Mississauga, Ontario L4W 5R6 www.bayer.ca Date of Revision: May 26, 2017 Submission Control No: 202824 © 2017, Bayer Inc. ® TM see www.bayer.ca/tm-mc _TRIQUILAR Product Monograph _ _Page 2 of 54_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................13 DRUG INTERACTIONS ..................................................................................................17 DOSAGE AND ADMINISTRATION ..............................................................................23 OVERDOSAGE ................................................................................................................26 ACTION AND CLINICAL PHARMACOLOGY ............................................................27 STORAGE AND STABILITY ..........................................................................................30 SPECIAL HANDLING INSTRUCTIONS .......................................................................30 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................30 PART II: SCIENTIFIC INFORMATION ..................................... اقرأ الوثيقة كاملة